Figure 1. Experimental design for HDL characterization following stroke event.

a) Plasma was acquired from non-stroke patients and from stroke patients 24 h after intervention post ischemic stroke event, and additionally at 96 h after intervention post ischemic stroke event. Plasma drawn from patients were used to measure lipid levels, and processed to measure cholesterol efflux capacity and HDL proteome components. Stroke severity was assessed upon patient presentation to clinic, and recovery assessed at 3 months post-stroke event. b) For HDL proteomics, particles were isolated by stepwise ultracentrifugation, digested, and analyzed first by tandem mass spectrometry to determine whole proteome composition, followed by targeted parallel reaction monitoring mass spectrometry to quantify changes in 41 protein components of HDL.